Bloomberg Talks
Eli Lilly CEO Dave Ricks Talks Weight Loss Drugs Success
Dec 10, 2024
In this discussion, Dave Ricks, CEO of Eli Lilly, shares insights on the company's groundbreaking weight-loss drugs, like Zepbound and terzepatide. He elaborates on their potential in treating addictive behaviors and combating the rising global obesity crisis. Ricks highlights the need for accessible treatments and the complexities of drug manufacturing. He also reflects on his career journey and the transformative impact these medications can have on patients' lives, emphasizing the importance of sustainable health changes.
43:31
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Eli Lilly is exploring the potential of its weight-loss drugs to also help in controlling addictive behaviors like substance abuse.
- The podcast discusses the significant impact of obesity medications, including Zepbound, on health issues and the challenges regarding insurance reimbursement.
Deep dives
Meta's Open Source AI Benefits All
Meta's open-source AI initiative provides free access to its models, opening opportunities for small businesses, startups, students, and researchers to innovate without financial barriers. This accessibility means that anyone can engage with AI technology, fostering a more diverse range of developments and applications. The rationale behind this move is that when AI is available to a broader audience, it stimulates creativity and innovation across various fields. Such initiatives can lead to significant advancements in technology that benefit society at large.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
